Who we are
BioCurate’s mission is to grow the Victorian and Australian biotech sector by translating medical research outputs into high quality preclinical candidates for the bio-pharmaceutical industry. A bold, collaborative venture, BioCurate was jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government. BioCurate is dedicated to identifying promising biomedical research discoveries and managing their translation into high quality pre-clinical candidates. BioCurate’s team of experts bring hands-on industry experience and a global track-record, providing a robust bridge between academia and industry within the biotechnology sector to accelerate the development of new therapies. We can help you change the future.
We bridge the gap
Our collaborative team of global biomedical experts bridge the gap between:
Academia + Industry
Ideas + Impact
Focus + Collaboration
Collaboration + Commercialisation
Research + Translation
The BioCurate team
Meet Jaclyn Sceneay
Director of Biology
Dr Jaclyn Sceneay is an immuno-oncologist with experience in small molecule and PROTAC drug discovery, and microbiome therapeutics.
Read more about Jaclyn
Meet our team
Meet Christopher Chan
Executive Director, Research and Development
Dr Christopher Chan is an immunologist with expertise in therapeutic antibody development, immuno-oncology, inflammation, innate myeloid and lymphocyte biology, and T cell biology.
Read more about Christopher
Meet our team
Meet Belinda Huff
Associate Director of Small Molecule Therapeutics
Dr Belinda Huff is a medicinal chemist with 8 years drug discovery experience in the pharmaceutical industry.
Read more about Belinda
Meet our team
Our team
170
More than 170 years of combined biotech/pharma industry experience
13
Directly involved in over 13 Investigational New Drug applications (INDs)
30
Responsible for 30 therapeutics currently in the clinic
$2.4B
Directly involved in deals worth a cumulative total of more than $2.4 billion
Twitter feed
;
@VCCCAlliance @MessengerBio @jumarbio @BioCurate @PeterMacCC @breakthroughvic @MIPS_Australia @WEHI_research @ONJCRI @UniMelb @JonnoBernardini Thanks to all the #I2T2023 sponsors!
@VCCCAlliance @MessengerBio @jumarbio Our panel on research commercialisation composed of Cathy Drinkwater from @BioCurate, Lucy Pearce from @PeterMacCC, Jerome Wielens from @breakthroughvic, Sam Cobb from Currus Biologics and moderated by Chris Porter from @MIPS_Australia. #I2T2023
📢 The #I2T2023 registrations are now sold out! See you all tomorrow!
🗓 Tuesday 5th of December
📍 Woodward Conference Centre (10th Floor, Melbourne Law Building, 185 Pelham St, Carlton).
🕣 Registration Desk opens at 8:30 AM (with tea & coffee provided), and 9AM start time.
BioCurate's Dr Cathy Drinkwater and Dr Andy Allen will be attending the #I2T2023 symposium next week. Cathy will be on the Research Commercialization Interactive Panel while Andy will be a judge at the Pitch Session. More details: https://bit.ly/3SYLn28 @Innovation2T
BioCurate is pleased to announce that Dr Kathy Nielsen has been appointed to the role of Chief Executive Officer. Dr Nielsen brings over 25yrs of experience in senior leadership and advisory roles primarily in the life science sector. Read more: https://bit.ly/47spfl4
BioCurate would like to welcome our newest Board Member, @alastair_hick. Currently the Chief Commercialisation Officer at @MonashUni, Alastair has a deep understanding of the translation of academic research, particularly in the life sciences. Read more: https://bit.ly/3GkpK4B
Professor Roger Daly, Head of the Signalling Network Laboratory, Monash Biomedicine Discovery Institute
“They [BioCurate] change your way of thinking as an academic researcher. They [BioCurate] highlight things which are really critical to potential commercialisation of a project, which you may not have thought of.”
Dr Linda Pullan, Director, Pullan Consulting, CA, USA and member of ISAG
“BioCurate brings deep industry perspective to select opportunities most likely to appeal to biotechnology and pharmaceutical companies, to confirm or extend the properties essential to entice those partners, and to communicate the science in a way that enables ready assessment of fit. This is hugely valuable to industry licensing efforts and will increase the probability of commercialization of the academic work.
I expect BioCurate to be on the top of the list of places where industry will hunt for early drug candidates.”
Professor Christoph Hagemeyer, Monash University
“We are very excited to bring our novel antibody from the bench closer to the bedside with help from the great team at BioCurate and make an impact in the cardiovascular disease indication. Our antibody targets a never before explored thrombotic mechanism that can potentially provide anti-thrombotic therapy without adverse effects.”
Penelope Lane, Senior Business Development Manager, the University of Melbourne
“Working with the team at BioCurate towards translation and commercialisation of medical research from the University of Melbourne has been a comprehensive, professional and considered experience, allowing the researchers, commercialisation teams and funds to successfully navigate investment into early stage medical research.
Collaboration of this nature is a best practice example in support of a truly innovative ecosystem for medical research.”
Professor Roger Daly, Head of the Signalling Network Laboratory, Monash Biomedicine Discovery Institute
“They [BioCurate] change your way of thinking as an academic researcher. They [BioCurate] highlight things which are really critical to potential commercialisation of a project, which you may not have thought of.”
Dr Linda Pullan, Director, Pullan Consulting, CA, USA and member of ISAG
“BioCurate brings deep industry perspective to select opportunities most likely to appeal to biotechnology and pharmaceutical companies, to confirm or extend the properties essential to entice those partners, and to communicate the science in a way that enables ready assessment of fit. This is hugely valuable to industry licensing efforts and will increase the probability of commercialization of the academic work.
I expect BioCurate to be on the top of the list of places where industry will hunt for early drug candidates.”
Professor Christoph Hagemeyer, Monash University
“We are very excited to bring our novel antibody from the bench closer to the bedside with help from the great team at BioCurate and make an impact in the cardiovascular disease indication. Our antibody targets a never before explored thrombotic mechanism that can potentially provide anti-thrombotic therapy without adverse effects.”
Penelope Lane, Senior Business Development Manager, the University of Melbourne
“Working with the team at BioCurate towards translation and commercialisation of medical research from the University of Melbourne has been a comprehensive, professional and considered experience, allowing the researchers, commercialisation teams and funds to successfully navigate investment into early stage medical research.
Collaboration of this nature is a best practice example in support of a truly innovative ecosystem for medical research.”